Below are the most recent publications written about "Multiple Sclerosis, Chronic Progressive" by people in Profiles.
-
Herranz E, Treaba CA, Barletta VT, Mehndiratta A, Ouellette R, Sloane JA, Ionete C, Babu S, Mastantuono M, Magon S, Loggia ML, Makary MM, Hooker JM, Catana C, Kinkel RP, Nicholas R, Klawiter EC, Magliozzi R, Mainero C. Characterization of cortico-meningeal translocator protein expression in multiple sclerosis. Brain. 2024 Jul 05; 147(7):2566-2578.
-
Sato S, Buonaccorsi J, Miehm JD, Lim J, Rajala C, Khalighinejad F, Ionete C, Kent JA, van Emmerik REA. Non-ambulatory measures of lower extremity sensorimotor function are associated with walking function in Multiple Sclerosis. Mult Scler Relat Disord. 2021 Aug; 53:103051.
-
Sato S, Lim J, Miehm JD, Buonaccorsi J, Rajala C, Khalighinejad F, Ionete C, Kent JA, van Emmerik REA. Rapid foot-tapping but not hand-tapping ability is different between relapsing-remitting and progressive multiple sclerosis. Mult Scler Relat Disord. 2020 Jun; 41:102031.
-
Cadavid D, Mellion M, Hupperts R, Edwards KR, Calabresi PA, Drulovic J, Giovannoni G, Hartung HP, Arnold DL, Fisher E, Rudick R, Mi S, Chai Y, Li J, Zhang Y, Cheng W, Xu L, Zhu B, Green SM, Chang I, Deykin A, Sheikh SI. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2019 09; 18(9):845-856.
-
Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdov? EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol. 2018 05; 17(5):405-415.
-
Herranz E, Giann? C, Louapre C, Treaba CA, Govindarajan ST, Ouellette R, Loggia ML, Sloane JA, Madigan N, Izquierdo-Garcia D, Ward N, Mangeat G, Granberg T, Klawiter EC, Catana C, Hooker JM, Taylor N, Ionete C, Kinkel RP, Mainero C. Neuroinflammatory component of gray matter pathology in multiple sclerosis. Ann Neurol. 2016 Nov; 80(5):776-790.
-
Cadavid D, Cohen JA, Freedman MS, Goldman MD, Hartung HP, Havrdova E, Jeffery D, Kapoor R, Miller A, Sellebjerg F, Kinch D, Lee S, Shang S, Mikol D. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. Mult Scler. 2017 01; 23(1):94-105.
-
Cadavid D, Jurgensen S, Lee S. Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis. PLoS One. 2013; 8(1):e53297.
-
Orbach R, Zhao Z, Wang YC, O'Neill G, Cadavid D. Comparison of disease activity in SPMS and PPMS in the context of multicenter clinical trials. PLoS One. 2012; 7(10):e45409.
-
Cadavid D, Tang Y, O'Neill G. [Responsiveness of the Expanded Disability Status Scale (EDSS) to disease progression and therapeutic intervention in progressive forms of multiple sclerosis]. Rev Neurol. 2010 Sep 16; 51(6):321-9.